Regulatory Challenges for Direct-to-Patient Clinical Trials

Posted 22 December 2017 By Andrea Zobel

placeholder+image On-site clinical trials may present a number of participation obstacles for individuals living at distances from clinical trial sites or for patients with mobility problems. Direct-to-patient clinical trials can be an alternative. This article reviews applicable regulations and analyzes current strategies for conducting direct-to-patient clinical trials using technologies, such as mobile 'apps' and wearables to report data, as well as the potential for sending trial drugs directly to participants. The author recommends ways to improve the regulatory landscape for direct-to-patient clinical trial participation and provides examples of best practices for working with regulatory agencies to ensure the efficacy and success of such trials.

Share this article:

Categories: Drugs, Clinical, Features, US, Europe, FDA, EMA, EC, ICH

Tags: Clinical Trials, Good Clinical Practice, Data Privacy, Direct-to-Patient Trials

Regulatory Exchange: Latest Updates From the Community